Most Clicked StoriesMore >


Study: Rebates have nothing to do with high drug prices

PCMA SmartBrief | Apr 24, 2017

A study conducted by consulting firm Visante found no link between rebates paid to pharmacy benefit managers and rising drug prices. "This study debunks the notion that the prices drugmakers set are contingent on the rebates they negotiate with PBMs," said PCMA President and CEO Mark Merritt in a statement. "Ironically, many higher-priced drugs involve little or no such rebates." American Pharmacy News (04/20)


Big Pharma faces steep patent cliff

PCMA SmartBrief | Apr 24, 2017

Pharma continues to raise prices faster than inflation

PCMA SmartBrief | Apr 28, 2017

Marathon Pharmaceuticals plans to close

PCMA SmartBrief | Apr 26, 2017

Supreme Court hears arguments in biosimilars "patent dance" case

PCMA SmartBrief | Apr 27, 2017

Study: PBM-negotiated rebates don't cause high drug prices

PCMA SmartBrief | Apr 26, 2017

Wholesaler makes pitch for independent drugstore business

PCMA SmartBrief | Apr 24, 2017

$60B worth of pharma products to lose patents through 2020

PCMA SmartBrief | Apr 27, 2017

Biogen announces positive study results on pricey orphan drug

PCMA SmartBrief | Apr 25, 2017

Supreme Court to hear 2 pharma cases this week

PCMA SmartBrief | Apr 24, 2017


Find PCMA SmartBrief Issues by Date:





Sign up for PCMA SmartBrief



Designed specifically for PBM industry professionals, PCMA SmartBrief is a FREE, daily e-mail newsletter. It provides the the most relevant and actionable PBM industry news in a quick, easy to read format. Learn more